Princeton BioMeditech
Private Company
Funding information not available
Overview
Founded in 1995, Princeton BioMeditech is a privately held, commercial-stage diagnostics company headquartered in Princeton, New Jersey. It has established itself as a pioneer in rapid point-of-care testing with an extensive menu of over 70 products spanning fertility, infectious disease, cardiac markers, drugs of abuse, tumor markers, veterinary, and food/environmental diagnostics. The company operates a US-based manufacturing facility certified under ISO 13485 and FDA regulations, serving a global customer base through a diversified distribution network. Its core strength lies in its patented, simple immunoassay technology platform, which enables reliable and accessible testing outside traditional lab settings.
Technology Platform
Patented simple and rapid immunoassay technology (likely lateral flow immunochromatography) enabling one-step, point-of-care tests. Supports a wide menu of qualitative and quantitative tests across multiple diagnostic categories.
Opportunities
Risk Factors
Competitive Landscape
PBM competes in the crowded rapid diagnostics market against major players like Abbott (BinaxNOW, Panbio), Roche (SARS-CoV-2 Antigen), QuidelOrtho (QuickVue, Sofia), and BD (Veritor). It differentiates through an exceptionally wide product menu spanning human and veterinary health. Competition is based on test accuracy, speed, ease of use, price, distribution reach, and brand recognition.